- French/American Contract Services Organisation boosts its offer to CNS/PNS 
drug development companies

Today Neuro-Sys, pharmacological Contract Research Services company 
specialising in the R&D and in vitro testing of molecules used to treat 
neurogenerative diseases in the Central Nervous System and Peripheral Nervous 
System, announces the launch of in vivo services.

This latest investment in state-of-the-art facilities allows Neuro-Sys to offer 
animal models and behavioural testing that uses digital tracking systems for 
the testing of candidate molecules, to its existing in vitro, and to new 
customers.

Of this latest development Chief Scientific Officer Noelle Callizot said: "We 
continue to conduct research to refine our knowledge of the pathological 
pathways and to develop our innovative in vitro models.  At the same time, it's 
important that our in vivo activity validates and enhances our in vitro work, 
allowing our customers a seamless process in their drug development programmes."

A record year 

The significant investment completes a record year for Neuro-Sys' in vivo 
business, with turnover increasing by 60% over the previous year.  The company 
was also voted a "Top 10 Bioanalytical services company" by Pharma Tech 
Outlook, "Best International drug development and discovery company for 2019" 
by Global Health & Pharma, UK, "Drug Development Company of the year" for 2020 
by Corporate Live Wire, UK and recently one of the "50 Leading Companies of the 
year" by US magazine The Silicon Review and "Research & Development reference 
for neurodegenerative diseases' by Biotech Finances, confirming its global 
standing.

About Neuro-Sys

Neuro-Sys is a French Contract Research Organization founded in 2013.  Its team 
of expert pharmacists and neuropharmacologists specialises in developing the 
understanding of neurodegenerative diseases of the central nervous system (CNS) 
and peripheral nervous systems (PNS) and the R&D of molecules used to treat 
them. It offers the screening of neuro active molecules using leading models 
that mimic their action in neurodegenerative diseases, and mode of action 
research.  

Neuro-Sys develops specific preclinical in vitro and in vivo models of CNS and 
PNS diseases. These models allow the understanding of the mode of action of 
molecules used in the treatment of diseases such as Alzheimer's, Parkinson's, 
Amyotrophic lateral sclerosis, Multiple sclerosis, Huntington's, 
Adrenoleukodystrophy, Multiple System Atrophy, Charcot-Marie Tooth. 

Logo - https://mma.prnewswire.com/media/1196886/Neuro_Sys_Logo.jpg 

Press contact: Cindy Sangnier
Email: cindy.sangnier@neuro-sys.com 

Source:  Neuro-Sys